deferiprone

Details

Files
Generic Name:
deferiprone
Project Status:
Complete
Therapeutic Area:
Transfusional iron overload
Manufacturer:
Chiesi Canada Corp.
Brand Name:
Ferriprox
Project Line:
Reimbursement Review
Project Number:
SR0741-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients with transfusional iron overload due to sickle cell disease or other anemias.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​For the treatment of patients with transfusional iron overload due to sickle cell disease or other anemias.
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openMay 10, 2022
Call for patient/clinician input closedJuly 04, 2022
Clarification:

- Patient input submission received from the Sickle Cell Awareness Group of Ontario and Thalassemia Foundation of Canada

Submission receivedJune 08, 2022
Submission acceptedJune 22, 2022
Review initiatedJune 23, 2022
Draft CADTH review report(s) provided to sponsor for commentSeptember 22, 2022
Deadline for sponsors commentsOctober 03, 2022
CADTH review report(s) and responses to comments provided to sponsorNovember 11, 2022
Expert committee meeting (initial)November 23, 2022
Draft recommendation issued to sponsorDecember 06, 2022
Draft recommendation posted for stakeholder feedbackDecember 15, 2022
End of feedback periodJanuary 06, 2023
Final recommendation issued to sponsor and drug plansJanuary 19, 2023
Final recommendation postedFebruary 07, 2023
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)February 03, 2023
CADTH review report(s) postedApril 27, 2023